Sobi buys out Pint Pharma to lock down Latin American oncology reach
What's the deal? Swedish biopharma SobiDealroom has a profile for this one. Try Dealroom → (Swedish Orphan Biovitrum) is acquiring the remaining shares of Pint PharmaDealroom has a profile for this one. Try Dealroom →, a Latin American specialist in distributing complex treatments such as cancer therapies. The deal, filed with Brazil's antitrust regulator Cade, gives Sobi 100% of Pharma InvestmentsDealroom has a profile for this one. Try Dealroom →, Pint's holding company. The transaction value was kept confidential.
Why now? The purchase extends a bet Sobi placed in 2025, when it paid $105 million (about R$525 million) for most of Pint's economic rights. That deal left Sobi with 60.47% of economic rights but only 19.99% of voting rights — the shares it is buying now.
What's the endgame? Pint runs a platform in seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. It handles regulatory approval, market access, and distribution to hospitals, clinics, and health operators, letting foreign drugmakers sell in the region without building operations from scratch.
The company says its platform reaches markets that together total more than 500 million people. The relationship predates Sobi's stake: the two have run a commercial partnership in Latin America since 2021, with Pint acting as a regional entry point for Sobi's drugs.
What changes? In Brazil, Pint sells a portfolio of licensed therapies for leukaemias, lymphomas, breast cancer, and rare diseases. These include Iclusig for certain leukaemias, Zynlonta for diffuse large B-cell lymphoma, Nerlynx for breast cancer, and Galafold for Fabry disease. The portfolio also carries Sobi's own drugs, such as Empaveli, Vonjo, and Kineret.
The signal: As Sobi expands its specialised portfolio internationally, owning the distribution network — rather than renting it — becomes more valuable. The Swedish firm, which reported revenue of 28.2 billion Swedish kronor (about $2.9 billion) in 2025, is consolidating control over a channel serving markets of over half a billion people.
Read more: InvestNews
Image credit: foteih
